Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00806143Phase 4Completed

Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression

Role: lead

NCT00796497Phase 4Completed

Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)

Role: lead

NCT01303536Phase 4Completed

Ondansetron Augmentation in Treatment-resistant OCD

Role: lead

All 3 trials loaded